Calamos Advisors’s Translational Development Acquisition Corp Units TDACU Stock Holding History

Calamos Advisors’s Portfolio TDACU Stock Details TDACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-375,000	Closed	-$4.03M	–	1323
2026 Q1	$4.03M	Hold	375,000	–	–	0.01%	590
2025 Q4	$4.39M	Hold	375,000	–	–	0.02%	552
2025 Q3	$4.02M	Hold	375,000	–	–	0.01%	565
2025 Q2	$3.94M	Hold	375,000	–	–	0.02%	575
2025 Q1	$3.8M	Hold	375,000	–	–	0.02%	547
2024 Q4	$3.76M	Buy	+375,000	New	+$3.76M	0.02%	541

Other funds holding TDACU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Calamos Advisors's TDACU Position: Q2 2026 in Review

Calamos Advisors sold out of Translational Development Acquisition Corp Units (TDACU) in Q2 2026, closing a stake of 375,000 shares — an estimated $4.03M sold.

Calamos Advisors first reported a position in TDACU in Q4 2024 and held it in 6 quarters. The position peaked at $4.39M in Q4 2025. 3 funds tracked by Wall St. Rank hold TDACU as of Q2 2026.

Calamos Advisors reported no remaining Translational Development Acquisition Corp Units position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 375,000 Translational Development Acquisition Corp Units shares in Q2 2026, an estimated $4.03M.
Calamos Advisors first reported a position in Translational Development Acquisition Corp Units in Q4 2024 and held it in 6 quarters.
Calamos Advisors's Translational Development Acquisition Corp Units position peaked at $4.39M in Q4 2025.
3 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Units as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.